ym 529 has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aota, Y; Imai, S; Kaneko, K; Saito, T; Taguri, M; Takahashi, M; Tanabe, H; Yamaguchi, Y | 1 |
| Fukata, S; Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kawada, C; Kurabayashi, A; Shuin, T | 1 |
2 other study(ies) available for ym 529 and Disease Exacerbation
| Article | Year |
|---|---|
Minodronate treatment improves low bone mass and reduces progressive thoracic scoliosis in a mouse model of adolescent idiopathic scoliosis.
Topics: Animals; Biomarkers; Bone and Bones; Bone Density; Combined Modality Therapy; Diphosphonates; Disease Models, Animal; Disease Progression; Female; Imidazoles; Mice; Restraint, Physical; Scoliosis; Severity of Illness Index; Treatment Outcome | 2018 |
Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Cell Line, Tumor; Diphosphonates; Disease Progression; Humans; Imidazoles; Immunohistochemistry; In Situ Hybridization; In Situ Nick-End Labeling; Interferon-alpha; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Osteoclasts; Xenograft Model Antitumor Assays | 2015 |